The reasons for this difference might be that Xu et al. did not distinguish the discrepancy of prognosis and genes expression between LGG and GBM, and they had not considered the effects of IDH mutation, TP53 mutation, ATRX mutation and 1p19q on the prognosis of glioma. Here, IDH1 is linked to central nervous system cancer.